"Given the ongoing shortages of branded medications such as Ozempic and Wegovy, WeightWatchers is committed to ensuring our members have access to effective alternatives," CEO Tara Comonte said in a statement. "With the addition of compounded semaglutide, we are expanding our offering to include a clinical weight management solution that is both accessible and affordable."
The company's decision comes amid skyrocketing demand for weight-loss medications like Wegovy and Eli Lilly's Zepbound, both of which have shown the potential to help patients lose up to 20% of their body weight. Shortages of these drugs have opened the door for drug compounders to step in under U.S. regulations, offering alternatives.
Once a dominant force in the weight-loss industry, WeightWatchers has faced significant challenges in recent years. The success of Wegovy and similar drugs from competitors like Eli Lilly has eroded demand for its traditional dieting services.
The new offering will start at $129 per month. Challenges in a Changing Industry...even after Tuesday's rally, WeightWatchers shares are still down 85% year to date.
Collection
[
|
...
]